A prospective study on the safety of sublingual immunotherapy in pregnancy

Allergy. 2012 Jun;67(6):741-3. doi: 10.1111/j.1398-9995.2012.02815.x. Epub 2012 Apr 5.


Background: The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported.

Methods: One hundred and fifty-five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 185 pregnancies. Twenty-four patients received sublingual immunotherapy for the first time during pregnancy. Follow-up data were analysed with regard to abortion, perinatal mortality, prematurity, toxaemia and congenital malformation. Two control groups did not receive immunotherapy; group A (85 patients) received budesonide 400 μg twice daily and group B (40 patients) received rescue salbutamol inhalation. All three groups were on appropriate avoidance measures.

Results: Six-year follow-up data for the sublingual immunotherapy group revealed an incidence of complications less than that in the general population and a higher incidence of complications in both control groups.

Conclusions: This study concludes that sublingual immunotherapy is safe during pregnancy and is also safe when initiated for the first time in a pregnant patient.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Sublingual
  • Adult
  • Albuterol / adverse effects
  • Allergens / administration & dosage*
  • Allergens / adverse effects*
  • Bronchodilator Agents / adverse effects
  • Budesonide / adverse effects
  • Desensitization, Immunologic / methods*
  • Female
  • Fetus / drug effects
  • Humans
  • Pregnancy Complications / epidemiology*
  • Pregnancy*
  • Young Adult


  • Allergens
  • Bronchodilator Agents
  • Budesonide
  • Albuterol